Aytu Biopharma (AYTU) Retained Earnings (2011 - 2026)
Aytu Biopharma (AYTU) posted quarterly Retained Earnings of -$347.8 million for Q1 2026, down 10.86% year-over-year from -$390.1 million in Q1 2025, and down 197.59% quarter-over-quarter from $356.4 million in Q4 2025.
Aytu Biopharma (AYTU) Retained Earnings (2011 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Retained Earnings for 16 consecutive years, with -$347.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 10.86% year-over-year to -$347.8 million; the TTM figure through Mar 2026 stood at -$347.8 million (down 10.86% YoY), while the FY2025 annual figure was -$333.5 million, down 4.24% from the prior year.
- Retained Earnings fell to -$347.8 million in Q1 2026 per AYTU's latest filing, from $356.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $356.4 million in Q4 2025 and bottomed at -$347.8 million in Q1 2026.
- Historically, Retained Earnings has averaged -$271.3 million across 5 years, with a median of -$312.5 million in 2023.
- Annual changes were most pronounced in 2022 — Retained Earnings plunged 61.01% — and 2025, when it jumped 212.16%.
- Aytu Biopharma's Retained Earnings stood at -$294.5 million in 2022, then declined by 6.12% to -$312.5 million in 2023, then slipped by 1.67% to -$317.7 million in 2024, then surged by 212.16% to $356.4 million in 2025, then slumped by 197.59% to -$347.8 million in 2026.
- Business Quant data shows AYTU's Retained Earnings at -$347.8 million in Q1 2026, $356.4 million in Q4 2025, and -$331.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 3.75 Bn |
| 10 | Aytu Biopharma | 23.86 Mn | -2.85 Mn | 7.60 Mn | 382.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -347.77 Mn |
| Dec 31, 2025 | 356.35 Mn |
| Sep 30, 2025 | -331.57 Mn |
| Jun 30, 2025 | -333.54 Mn |
| Mar 31, 2025 | -313.72 Mn |
| Dec 31, 2024 | -317.71 Mn |
| Sep 30, 2024 | -318.50 Mn |
| Jun 30, 2024 | -319.97 Mn |
| Mar 31, 2024 | -315.36 Mn |
| Dec 31, 2023 | -312.50 Mn |
| Sep 30, 2023 | -312.20 Mn |
| Jun 30, 2023 | -304.13 Mn |
| Mar 31, 2023 | -301.70 Mn |
| Dec 31, 2022 | -294.47 Mn |
| Sep 30, 2022 | -287.78 Mn |
| Jun 30, 2022 | -287.08 Mn |
| Mar 31, 2022 | -270.77 Mn |
| Dec 31, 2021 | -217.70 Mn |
| Sep 30, 2021 | -206.15 Mn |
| Jun 30, 2021 | -178.30 Mn |